



UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: PTQ-0058  
Inventors: Van Eyk et al.  
Serial No.: 10/824,027  
Filing Date: April 14, 2004  
Examiner: Desai, Anand U.  
Group Art Unit: 1653  
Title: Methods and Compositions for Modulating  
Proteins Modified in Preconditioning  
Against Ischemia/Hypoxia

"Express Mail" Label No. EV583918287US  
Date of Deposit February 11, 2005

I hereby certify that this paper is being deposited with the  
United States Postal Service "Express Mail Post Office  
to Addressee" service under 37 CFR 1.10 on the date  
indicated above and is addressed to the Commissioner for Patents  
Post Office Box 1450, Box Restriction Requirement, Alexandria, VA 22313-1450

By Kathleen A. Tyrell  
Typed Name: Kathleen A. Tyrell, Reg. No. 38,350

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information  
Disclosure Statement is being filed either within three

months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is attached hereto; or

( ) Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,




Kathleen A. Tyrrell  
Registration No. 38,350

Date: February 11, 2005

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

FOIA b7 - PTO-1449 Modified  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce	Docket No. <b>PTQ-0058</b>	Serial No. <b>10/824,027</b>
	Applicant <b>Van Eyk et al.</b>	
	Filing Date <b>April 14, 2004</b>	Group <b>1653</b>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AA	Hanley et al., " $K_{ATP}$ channel-independent targets of diazoxide and 5-hydroxydecanoate in the heart", Journal of Physiology 2002 542.3:735-741
	AB	Hanley et al., "Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria", Journal of Physiology 2002 544.3:687-693
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>